Combination Therapy With MDM2 and MEK Inhibitors Is Effective in Patient-Derived Models of Lung Adenocarcinoma With Concurrent Oncogenic Drivers and MDM2 Amplification

Arielle Elkrief, Igor Odintsov, Vladimir Markov, Rebecca Caeser, Paweł Sobczuk, Sam E. Tischfield, Umesh Bhanot, Chad Vanderbilt, Emily H. Cheng, Alexander Drilon, Gregory J. Riely, William W. Lockwood, Elisa de Stanchina, Vijaya G. Tirunagaru, Robert C. Doebele, Àlvaro Quintanal-Villalonga, Charles M. Rudin, Romel Somwar, Marc Ladanyi